단백질체학 시장 규모, 점유율 및 동향 분석 보고서 : 제품·서비스별, 용도별, 기술별, 지역별 및 부문별 예측(2026-2033년)

Proteomics Market Summary

The global proteomics market size was valued at USD 38.4 billion in 2025 and is projected to grow from USD 43.7 billion in 2026 to USD 97.7 billion by 2033, at a CAGR of 13.3% from 2026 to 2033. The North American market held the largest share of 45.3% in 2025. The market is witnessing significant growth driven by the rising prevalence of chronic and infectious diseases, growing preference for personalized medicine, and the increasing demand for rapid & advanced diagnostic solutions in target disease treatment.

Global Proteomics Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global proteomics market report on the basis of product & service, application, technology, and region.

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Reagents & Consumables
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Diagnostics
• Drug Discovery
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Microarray Instruments
• X-Ray Crystallography
• Spectrometry
• Chromatography
• Protein Fractionation Systems
• Electrophoresis
• Surface Plasma Resonance (SPR) Systems
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. Technology
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Impact Analysis
    • 3.3.1.1. Advancements in SELEX and high-throughput screening technologies
    • 3.3.1.2. Rising demand for targeted therapeutics and precision medicine
    • 3.3.1.3. Increasing adoption of proteomics in diagnostics and biosensor applications
  • 3.3.2. Market Restraint Impact Analysis
    • 3.3.2.1. High cost associated with aptamer development and commercialization
    • 3.3.2.2. Limited number of approved aptamer-based therapeutics
  • 3.3.3. Market Challenges Analysis
  • 3.3.4. Market Opportunity Analysis
• 3.4. Case Study Insights
• 3.5. Business Environment Analysis
  • 3.5.1. PESTLE Analysis
  • 3.5.2. PORTER'S Five Forces Analysis

Chapter 4. Proteomics Market: Product & Service Business Analysis

• 4.1. Product & Service Market Share, 2025 & 2033
• 4.2. Product & Service Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
• 4.5. Reagents & Consumables
  • 4.5.1. Reagents & Consumables Market, 2021 - 2033 (USD Million)
• 4.6. Services
  • 4.6.1. Service Market, 2021 - 2033 (USD Million)

Chapter 5. Proteomics Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Clinical Diagnostics
  • 5.4.1. Clinical Diagnostics Market, 2021 - 2033 (USD Million)
• 5.5. Drug Discovery
  • 5.5.1. Drug Discovery Market, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Other Applications Market, 2021 - 2033 (USD Million)

Chapter 6. Proteomics Market: Technology Business Analysis

• 6.1. Technology Market Share, 2025 & 2033
• 6.2. Technology Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Surface Plasma Resonance (SPR) Systems
  • 6.4.1. Surface Plasma Resonance (SPR) Systems Market, 2021 - 2033 (USD Million)
• 6.5. Microarray Instruments
  • 6.5.1. Microarray Instruments Market, 2021 - 2033 (USD Million)
• 6.6. X-Ray Crystallography
  • 6.6.1. X-Ray Crystallography Market, 2021 - 2033 (USD Million)
• 6.7. Spectrometry
  • 6.7.1. Spectrometry Market, 2021 - 2033 (USD Million)
• 6.8. Chromatography
  • 6.8.1. Chromatography Market, 2021 - 2033 (USD Million)
• 6.9. Protein Fractionation Systems
  • 6.9.1. Protein Fractionation Systems Market, 2021 - 2033 (USD Million)
• 6.10. Electrophoresis
  • 6.10.1. Electrophoresis Market, 2021 - 2033 (USD Million)

Chapter 7. Proteomics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 7.4. North America
  • 7.4.1. North America Proteomics Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Proteomics Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Proteomics Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Proteomics Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Proteomics Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Proteomics Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2025
• 8.3. Strategy Mapping
• 8.4. Company Profiles/Listing
  • 8.4.1. Illumina, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Agilent Technologies, Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Bio-Rad Laboratories, Inc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Thermo Fisher Scientific, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Bruker Corporation
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. F. Hoffmann-La Roche Ltd.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Waters Corporation
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Merck KGaA
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Danaher
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Standard BioTools Inc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Seer, Inc
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. QIAGEN
    • 8.4.12.1. Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Strategic Initiatives